55 and older, any sex, with Multimorbidity or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - PainPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
5
0 – 8
6-week
Group
Value
95% CI
Intervention
4
1 – 6
3-month
Group
Value
95% CI
Intervention
5
2 – 7
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - TirednessPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
3
2 – 5
6-week
Group
Value
95% CI
Intervention
3
3 – 4
3-month
Group
Value
95% CI
Intervention
6
3 – 7
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - DrowsinessPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
2
0 – 5
6-week
Group
Value
95% CI
Intervention
3
0 – 4
3-month
Group
Value
95% CI
Intervention
5
2 – 6
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - NauseaPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
0
0 – 0
6-week
Group
Value
95% CI
Intervention
0
0 – 0.3
3-month
Group
Value
95% CI
Intervention
1
0 – 2.5
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - Lack of AppetitePrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
0
0 – 0
6-week
Group
Value
95% CI
Intervention
1
0 – 6
3-month
Group
Value
95% CI
Intervention
3.3
1 – 4
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - Shortness of BreathPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
0
0 – 4
6-week
Group
Value
95% CI
Intervention
3
1 – 4
3-month
Group
Value
95% CI
Intervention
5
3 – 5
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - DepressionPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
0
0 – 3
6-week
Group
Value
95% CI
Intervention
3
1 – 5
3-month
Group
Value
95% CI
Intervention
4.5
1 – 6
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - AnxietyPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
0
0 – 5
6-week
Group
Value
95% CI
Intervention
2
0.5 – 6
3-month
Group
Value
95% CI
Intervention
2.5
0 – 5
Symptom Burden Assessed by Edmonton Symptom Assessment System (ESAS) Score - Well-beingPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
The ESAS questionnaire is used to rate the intensity of common symptoms including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath; with ratings ranging from 0 (none, best) to 10 (worst).
Baseline
Group
Value
95% CI
Intervention
5
0 – 7
6-week
Group
Value
95% CI
Intervention
4
3.3 – 6.5
3-month
Group
Value
95% CI
Intervention
3.3
2 – 5
Quality of Life Assessed by Short Form Survey (SF-36) Score - Physical FunctioningPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
Short Form Survey (SF-36) is a 36-item self-reported quality of life that covers 8 domains; score range 0 to 100. Higher score is better quality of life.
Baseline
Group
Value
95% CI
Intervention
50
12.5 – 62.5
6-week
Group
Value
95% CI
Intervention
40
25 – 60
3-month
Group
Value
95% CI
Intervention
32.5
10 – 65
Quality of Life Assessed by Short Form Survey (SF-36) Score - Role PhysicalPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
Short Form Survey (SF-36) is a 36-item self-reported quality of life that covers 8 domains; score range 0 to 100. Higher score is better quality of life.
Baseline
Group
Value
95% CI
Intervention
25
0 – 25
6-week
Group
Value
95% CI
Intervention
0
0 – 100
3-month
Group
Value
95% CI
Intervention
0
0 – 75
Quality of Life Assessed by Short Form Survey (SF-36) Score - Role EmotionalPrimary· Baseline, 6-weeks post intervention, 3 months post intervention
Short Form Survey (SF-36) is a 36-item self-reported quality of life that covers 8 domains; score range 0 to 100. Higher score is better quality of life.
Baseline
Group
Value
95% CI
Intervention
33.33
0 – 100
6-week
Group
Value
95% CI
Intervention
33.33
0 – 100
3-month
Group
Value
95% CI
Intervention
16.67
0 – 100
Sponsor's own description
Multimorbidity is common and is the coexistence of two or more chronic conditions in the same individual. People with multimorbidity suffer from a high symptom burden, directly affecting quality of life (QOL). Hospitalization can be a window of opportunity to initiate interventions to promote recovery and resilience and enhance QOL. However, interventions targeting the symptom trajectory and burden of patients with multimorbidity are lacking. Thus, the investigators envisage a nurse-led pre-discharge intervention augmented by telephone support, focusing on care coordination and symptom management. This approach is anticipated to help reduce symptom burden and improve QOL.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
· Phase 1, PHASE2
· recruiting
NCT06605807 — Optimizing Prescribing Decisions for Hospitalized Older Adults With Chronic Conditions
· NA
· recruiting
NCT07211750 — Integrated Care for Older Adults With Major Depression and Physical Multimorbidity - The I-CONNECT
· NA
· recruiting
NCT07205692 — Multimorbidity and Cardiovascular Risk Factors After Renal Transplant
· recruiting
NCT06975501 — Community-Empowerment and Environmental Enrichment-based Co-management (CEEEC) Model and Mechanisms for Improving Health
· NA
· active not recruiting
Other Johns Hopkins University trials
Trials by the same sponsor.
NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety
· NA
· not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder
· Phase 2
· not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea
· Phase 1, PHASE2
· not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use
· NA
· not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05985044.